Menarini Intl Drug Patent Portfolio
Menarini Intl owns 1 orange book drug protected by 10 US patents Given below is the list of Menarini Intl's drug patents along with their expiration dates.
Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
---|---|---|---|
US6303607 | Method for administering a sustained release ranolanolazine formulation | 27 May, 2019 | Expired |
US6369062 | Sustained release ranolazine formulations | 27 May, 2019 | Expired |
US6479496 | Methods for treating angina with ranolazine | 27 May, 2019 | Expired |
US6503911 | Sustained release ranolazine formulations | 27 May, 2019 | Expired |
US6525057 | Sustained release ranolazine formulations | 27 May, 2019 | Expired |
US6562826 | Sustained release ranolazine formulations | 27 May, 2019 | Expired |
US6617328 | Sustained release ranolazine formulations | 27 May, 2019 | Expired |
US6620814 | Sustained release ranolazine formulations | 27 May, 2019 | Expired |
US6852724 | Sustained release ranolazine formulations | 27 May, 2019 | Expired |
US6864258 | Sustained release ranolazine formulations | 27 May, 2019 | Expired |
Latest Legal Activities on Menarini Intl's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Menarini Intl.
Activity | Date | Patent Number |
---|---|---|
File Marked Found | 20 Dec, 2016 | US6620814 (Litigated) |
File Marked Found | 15 Dec, 2016 | US6525057 (Litigated) |
File Marked Found | 12 Dec, 2016 | US6525057 (Litigated) |
Post Issue Communication - Certificate of Correction | 11 Aug, 2015 | US6562826 (Litigated) |
Case Docketed to Examiner in GAU
Critical
| 05 Aug, 2015 | US6562826 (Litigated) |
Post Issue Communication - Certificate of Correction | 19 Mar, 2015 | US6620814 (Litigated) |
Post Issue Communication - Certificate of Correction | 21 Jan, 2015 | US6852724 (Litigated) |
Correspondence Address Change
Critical
| 01 Mar, 2012 | US6852724 (Litigated) |
Correspondence Address Change
Critical
| 01 Mar, 2012 | US6617328 (Litigated) |
Correspondence Address Change
Critical
| 01 Mar, 2012 | US6864258 (Litigated) |
Correspondence Address Change
Critical
| 01 Mar, 2012 | US6562826 (Litigated) |
Correspondence Address Change
Critical
| 01 Mar, 2012 | US6503911 (Litigated) |
Correspondence Address Change
Critical
| 01 Mar, 2012 | US6525057 (Litigated) |
Correspondence Address Change
Critical
| 01 Mar, 2012 | US6620814 (Litigated) |
Post Issue Communication - Certificate of Correction | 16 Jun, 2011 | US6620814 (Litigated) |
Menarini Intl's Family Patents
Menarini Intl Drug List
Given below is the complete list of Menarini Intl's drugs and the patents protecting them.
1. Ranexa
Ranexa is protected by 10 patents, out of which all have expired. Check out its patent list below.
Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
---|---|---|---|
US6303607 | Method for administering a sustained release ranolanolazine formulation |
27 May, 2019
(5 years ago)
| Expired |
US6369062 | Sustained release ranolazine formulations |
27 May, 2019
(5 years ago)
| Expired |
US6479496 | Methods for treating angina with ranolazine |
27 May, 2019
(5 years ago)
| Expired |
US6503911 | Sustained release ranolazine formulations |
27 May, 2019
(5 years ago)
| Expired |
US6525057 | Sustained release ranolazine formulations |
27 May, 2019
(5 years ago)
| Expired |
US6562826 | Sustained release ranolazine formulations |
27 May, 2019
(5 years ago)
| Expired |
US6617328 | Sustained release ranolazine formulations |
27 May, 2019
(5 years ago)
| Expired |
US6620814 | Sustained release ranolazine formulations |
27 May, 2019
(5 years ago)
| Expired |
US6852724 | Sustained release ranolazine formulations |
27 May, 2019
(5 years ago)
| Expired |
US6864258 | Sustained release ranolazine formulations |
27 May, 2019
(5 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Ranexa's drug page
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List